Medical use of certain chemical compounds and pharmaceutical ingredients containing them. Mglu2 / 3 negative Western Sahara modulation compound for tea treatment, especially for autism treatment. 7. Pharmaceutical ingredients for tea processing, including a current compound and a drug acceptable carrier. Requirement 1: treatment with negative mglu2 / 3 Western Sahara modulator,Prevent and / or delay the development of central nervous system conditions, as neurodevelopmental defects cause multiple mglu2 / 3 receptor activation in the central nervous system, and / or can be corrected by negatively symmetric regulation of mglu2 / 3 receptor activation. Claim 5: a negative mglu2 / 3 Western Sahara modulator is selected from one formula compound (1) and one formula compound (2) according to any one use of claims 1-4,where: E and J are N, G is C and one of L and M is N and the other is CH； or L and G are N, E is C and J and M are CH； or J, G and L are N, E is C and M is CH； or E and L are N, J and M are CH and G is C； A is selected from the group consisting of phenyl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyridazin-2-yl, pyridazin- 3-yl, thiazol-2-yl, thiazol-5-yl and thiophene-2-yl, which are optionally substituted with one to four Rᵃ；B selected from a group consisting of methyl picolinate, [1,2,4] oxadiazolilo, pirrolilo, 1H pirazolilo, piridinil, [1,2,4] triazolo, tiazolo, pirimidinilo and tiofenil, each group can be selectively replaced by c83318326 tar；C is an optionally substituted aryl or optionally substituted 5- or 6-membered heteroaryl, in which the substituents are selected from the group consisting of: i) halo, ii) nitro, iii) C₁₋₆ alkyl optionally substituted with hydroxy , iv) NRᵃᵃRᵇᵇ,wherein Rᵃᵃ and Rᵇᵇ are independently H, C₁₋₆ alkyl or - (CO) C₁₋₆ alkyl,(v) S-lessor c8321c833126；vi) - (SO₂) -OH, vii) - (SO₂) -alkyl C₁₋₆,VIII - (so832222) - No. 7580； No. 758080； No. 7496； (74966)；wherein Rᶜᶜ and Rᵈᵈ are independently: a)
